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1. Introduction
Inflammatory Bowel Disease (IBD) classified with Ulcerative Colitis (UC) and Crohn Dis‐
ease (CD) is an idiopathic, life-long, destructive chronic inflammatory disease in gastrointes‐
tinal tract [1] and probably multi-factorial disease caused by interplay of the external and
internal environment. Little is known about the mechanism of pathogenesis of the disease
but it has been reported that immunological mechanisms are involved in etiology. Under
normal situations, the intestinal mucosa is in a state of controlled inflammation regulated by
a delicate balance of pro-inflammatory (tumor necrosis factor [TNF]-alpha, interferon [IFN]-
gamma, interleukin [IL]-1, IL-6, IL-12 and anti-inflammatory cytokines (IL-4, IL-10, IL-11),
where particularly, IL-6 stimulates T-cell and B-cell proliferation and differentiation.
Therefore, the mucosal immune system is the central effect or of intestinal inflammation and
injury, with cytokines playing a central role in modulating inflammation [2,3].
During last a couple of decade, the therapeutic agents for IBD have been changed rapidly
and anti-inflammatory agents such as corticosteroid and salicylates or its metabolite were
used but recently biological agents are introduced. Emerging changes in IBD medications or
their use for an instance, balsalazid, budesonide, 5-aminosalicylate (5-ASA) and purine ana‐
logues such as azathioprine are improvements in conventional application, additionally,
mycophenolate mofetil (MMF), thalidomide and heparin are newly introduced into IBDther‐
apy [4-6].
On the contrary, advances in molecular technology have enabled the development of novel
and potentially effective targeted therapies with anti-TNF particularly infliximab, interfer‐
on-gamma and interleukin [7, 8]. Nevertheless, biologically active agents have some prob‐
lems in terms of long termstorage conditions and immune-toxicity, additionally
biocompatibility against major histological complex (MHC) of immunoglobulin G, which
may cause in inconvenience of patient compliance and more expenditure. Thus, the great in‐
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terest has been focused to the interplay between the adaptive and innate natural sources not
only to achieve a better understanding of the immune-pathogeneses of inflammatory bowel
disease but to identify targets for even more potent intervention [9-11].
Furthermore, colonic drug delivery has gained increased importance not just for the treat‐
ment of local diseases associated with the colon but also for its potential improvement relat‐
ed with adverse events such as ileocecal junction (ICJ) barrier and small volume capacity.
The various strategies for targeting orally administered drugs to the colon are consisted of
pH dependent polymers, azo-polymers, covalent linkage of a drug with a carrier, formula‐
tion of timed released systems, drug carriers that are degraded specially by colonic bacteria
and, bio-adhesive.
2. Natural products with anti-inflammatory and anti-tumor activity
In the field of pharmaceutics, the synthetic chemistry is gradually made more efficient and
precise, but also gradually changing into bio-technological applications and a return to the
infinitely more variable and complex chemistry of Nature.
Organisms in Nature produce secondary metabolites with the specific purpose to gain evo‐
lutionary advantages in the competition for example living space and in the search for nu‐
trients. With an estimated numbers of more than 300 thousands species of plants and
probably close to two million species of various organisms, the biodiversity of Nature re‐
mains an unparalleled reservoir of biological and chemical diversity. However, most of the
biodiversity is as yet unexplored.
Most important thing is the development of strategies for selection, isolation and characteri‐
zation with the objective to discover unique bioactive chemical structures with drug poten‐
tial, and to reveal unknown targets, by studying the evolutionary structure–activity
optimization in Nature.
In addition to the possibility to discover new drug candidates for drug development, bioac‐
tive natural projects have potential as pharmacological tools, intermediates, or templates for
synthesis of drugs.
The increased uses of herbal remedies, which contain complex mixtures of natural products,
need intensified scientific studies to establish efficacy and safety of these types of products
as well as clinical studies.
With the increasing interest for environmental aspects, green chemistry, and a sustainable
use of natural products, this renewal could have a strategic position in bridging chemistry
and biology.
The correlation between the chemical structures responsible for the shown bioactivity needs
to be studied to understand the observation on a molecular level using both in vivo, in vitro
and in silico methods [12].Explanatory model the interdisciplinary nature of pharmacogn‐
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ocy interpreted in an explanatory model presented by Larsson and co-workers [13]. In this
model a clearly defined role is presented for aspects of informatics, includingbio- and che‐
mo-informatics. The studies of pure natural products against colon cancer are now in focus.
Another project is focused on bioengineering of circular proteins, so called cyclotides, to cre‐
ate new structure–activity relationships. Novel strategies are developed for efficient predic‐
tion and selection of organisms and molecules and bioinformatics tools to predict novel
targets based on lateral gene transfer.
A scientific platform has been built in our long-term research on anti-inflammatory natural
products as demonstrated in a number of publications and doctoral theses. Many differ‐
entchemical structures have been discovered, and chemically and pharmacologically charac‐
terized using bioassay-guided isolation procedures. In vivo methods such as rat paw and
mouse ear edema was used and later followed by in vitro enzyme and cell based methods.
Two systems have been established to enable investigations of the effects of natural com‐
pounds on COX-2. The first method developed was an in vitro method suitable for measur‐
ing inhibition of COX-2 catalyzed prostaglandin E2 biosynthesis, based on scintillation
proximity assay technology [14]. The second system comprises acell model, suitable for
studying the effects of compounds on COX-2 and inducible nitric oxide synthase (iNOS) at
different cellular levels, including the effects on mRNA, protein, prostaglandin E2, and ni‐
tric oxide levels [15].
In later years the project has developed towards enzyme inhibitors related to anti-tumor ac‐
tivity, especially in colon cancer. It has been shown that the process of inflammation and ex‐
pression of cyclooxygenase-2 is important in colon carcinogenesis.Another important factor
is diet. Many food python-chemicals have been shown to exert anti-inflammatory activity in
vitro, and may act as cancer chemo-preventive agents [16, 17]. A vegetarian diet rich in py‐
thon-chemicals may prevent colon carcinogenesis by affecting biochemical processes in the
colonic mucosa. It has been shown that intact fecal water (water phase) samples from hu‐
man volunteers significantly decreased prostaglandin production and COX-2 expression in
colonic cells. NMR spectroscopy and multivariate data analysis were later used for further
analysis of the composition of the fecal waters and to trace the COX-2 inhibiting activity [18,
19]. The wealth of different natural products with experimentally demonstratedCOX inhibi‐
tory effects and an urge to understand and characterize their structural diversity was the
starting point for the application of chirography in our natural products research.
The identification from chemo graphic  analyses  of  some specific  groups of  compounds,
including a set of cardiac glycosides, as being of prime importance was further establish‐
ed  in  a  screening  of  a  large  number  of  natural  products  for  activity  against  colorectal
cancer where several cardiac glycosides showed significant activity. This activity was fur‐
ther confirmed in primary cells from colon cancer patients. Cardiac glycosides have been
reported  to  exhibit  cytotoxic  activity  against  several  different  cancer  types,  but  studies
against colorectal cancer are lacking. Drugs for clinical treatment of colon cancer are usu‐
ally used in combination to overcome the problem with drug resistance and to increase
the activity.  Therefore,  selected cardiac glycosides were tested in combination with four
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clinically relevant standard cyto-toxic  drugs (5-fluorouracil,  oxaliplatin,  cisplatin,  irinote‐
can) to screen for synergistic effects.
The combination of digoxin and oxaliplatin exhibited synergism including the otherwise
highly drug resistant HT29 cell line [20]. In depth studies are now in progress necessary to
understand these effects on a molecular level.
A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and
Wnt/EGFR/NF-kappaB-signaling pathways, which provide evidence that the plant flavo‐
noid fisetin can induce apoptosis and suppress the growth of colon cancer cells by inhibition
of COX2- and Wnt/EGFR/NF-kappaB-signaling pathways and suggest that fisetin could be a
useful agent for prevention and treatment of colon cancer [21].The contribution of plukene‐
tione A to the antitumor activity of Cuban propolis was assumed that plukenetione A con‐
tributes to the antitumor effect of Cuban propolis mainly by targeting to poisomerase I as
well as DNA polymerase[22].Aberrant Wnt/beta-catenin signaling has recently been impli‐
cated in tumor genesis. On the basis of screening program targeting inhibition of TCF/beta-
catenin transcriptional activity, a plant extract of Eleutherine palmfolia was selected as a hit
sample. Activity-guided fractionations led to the isolation of 15 naphthalene derivatives
(1-15), including 4 new glycosides, eleutherinosides B-E (1-4), and 10 of the 15 compounds
showed strong activities with high viability among 293T cells, whose data showed that 2
and 9 inhibited the transcription of TCF/beta-catenin in SW480 colon cancer cells in a dose-
dependent manner and selective cytotoxicity against three colorectal cancer cell lines. In ad‐
dition, treatment with 9 led to a significant decrease in the level of nuclear beta-catenin
protein, suggesting this reduction to have resulted in the inhibitory effect of 9 on the tran‐
scription of TCF/beta-catenin [23].
Penta-cyclic triterpene acids are known mainly for their anti-antigenic effects as well as their
differentiation inducing effects. In particular, lupane-type triterpenes, such as botulin, bo‐
tulnic acid and lupeol, display anti-inflammatory activities which often accompany immune
modulation. Tri-terpene acids as well as triterpene mono-alcohols and diols also show an
anti-oxidative potential. The pharmacological potential of triterpenes of the lupane, olea‐
nane or urbane type for cancer treatment seems high; although up to now no clinical trial
has been published using these tri-terpenes in cancer therapy. They provide a multi-target
potential for coping with new cancer strategies. Whether this is an effective approach for
cancer treatment has to be proven. Because various triterpenes are an increasingly promis‐
ing group of plant metabolites, the utilization of different plants as their sources is of inter‐
est. Parts of plants, for example birch bark, rosemary leaves, apple peel and mistletoe shoots
are rich in triterpenes and provide different triterpene compositions [24].
Advanced cancer is a multi-factorial disease that demands treatments targeting multiple cel‐
lular pathways. Chinese herbal cocktail which contains various phytochemicals may target
multiple dys-regulated pathways in cancer cells and thus may provide an alternative/
complementary way to treat cancers. Previously reported that the Chinese herbal cocktail
Tien-Hsien Liguid (THL) can specifically induce apoptosis in various cancer cells and have
immuno-modulating activity.Further, evaluated the anti-metastatic, anti-angiogenic and an‐
ti-tumor activities of THL [25]. Dietary grape seed extract (GSE) effectiveness in preventing
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azoxymethane (AOM)-induced aberrant crypt foci (ACF) formation. GSE-feeding inhibited
AOM-induced cell proliferation but enhanced apoptosis in colon including ACF, together
with a strong decrease in cyclin D1, COX-2, iNOS, and survivin levels and showed that GSE-
feeding also decreased AOM-caused increase in beta-catenin and NF-kappaB levels in colon
tissues[26].Grifolin, a secondary metabolite isolated from the fresh fruiting bodies of the
mushroom Albatrellus confluens, has been shown to inhibit the growth of some cancer cell
lines in vitro by induction of apoptosis An apoptosis-related gene expression profiling anal‐
ysis provided a clue that death-associated protein kinase 1 (dapk1) gene was up-regulated at
least twofold in response to grifolin treatment in nasopharyngeal carcinoma cell CNE1. Fur‐
ther,investigated the role of DAPK1 in apoptotic effect induced by grifolin and observed
that protein as well as mRNA level of DAPK1 was induced by grifolin in a dose-dependent
manner in nasopharyngeal carcinoma cell CNE1. It was found that grifolin increased both
Ser392 and Ser20 phosphorylation levels of transcription factor p53 protein, which could
promote its transcriptional activity. Moreover, induced by grifolin, the recruitment of p53 to
dapk1 gene promoter was confirmed to enhance markedly using EMSA and ChIP assays
analysis. The involvement of DAPK1 in grifolin-induced apoptosis was supported by the
studies that introducing siRNA targeting DAPK1 to CNE1 cells remarkably interfered grifo‐
lin-caused apoptotic effect as well as the activation of caspase-3. Grifolin induced up-regula‐
tion of DAPK1 via p53 was also observed in tumor cells derived from human breast cancer
and human colon cancer. Up-regulation of DAPK1 via p53-DAPK1 pathway is an important
mechanism of grifolin contributing to its ability to induce apoptotic effect. Since growing
evidence found a significant loss of DAPK1 expression in a large variety of tumor types, gri‐
folin may represent a promising candidate in the intervention of cancer via targeting
DAPK1[27]. Five derivatives of the natural product sansalvamide A that are potent against
multiple drug-resistant colon cancer cell lines were identified. These analogs share no struc‐
tural homology to current colon cancer drugs, are cytotoxic at levels on par with existing
drugs treating other cancers, and demonstrate selectivity for drug-resistant colon cancer cell
lines over noncancerous cell lines. Thus, we have established sansalvamide A as a privileged
structure for treating multiple drug-resistant colon cancers [28]. Anti-cancer activities of the
ethanol extract of Ka-mi-kae-kyuk-tang (KMKKT) targeting angiogenesis, apoptosis and
metastasis without any adverse effect on the body weight. This formula merits serious con‐
sideration for further evaluation for the chemoprevention and treatment of cancers of multi‐
ple organ sites[29].The effect of aged garlic extract (AGE) on the growth of colorectal cancer
cells and their angiogenesis, which are important microenvironmental factors in carcinogen‐
esis. AGE (aged garlic extract) could prevent tumor formation by inhibiting angiogenesis
through the suppression of endothelial cell motility, proliferation, and tube formation. AGE
would be a good chemo-preventive agent for colorectal cancer because of its anti-prolifera‐
tive action on colorectal carcinoma cells and inhibitory activity on angiogenesis. Aged garlic
extract (AGE) has manifold biological activities including immune-modulated and anti-oxi‐
dative effects. It is used as a major component of nonprescription tonics and cold-prevention
medicines or dietary supplements [30, 31].
Transcription factor NF-kappaB is constitutively active in many human chronic inflammato‐
ry diseases and cancers. Epoxy quinone A monomer (EqM), a synthetic derivative of the nat‐
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ural product epoxyquinol A, has previously been shown to be a potent inhibitor of tumor
necrosis factor-alpha (TNF-alpha)-induced activation of NF-kappaB [32]. EqM also effective‐
ly inhibits the growth of human leukemia, kidney, and colon cancer cell lines in the NCI's
tumor cell panel. Among six colon cancer cell lines, those with low amounts of constitutive
NF-kappaB DNA-binding activity are generally more sensitive to growth inhibition by EqM.
Therefore, EqM inhibits growth and induces cell death in tumor cells through a mechanism
that involves inhibition of NF-kappaB activity at multiple steps in the signaling pathway.
Colorectal cancer, the second most frequent diagnosed cancer in the US, causes significant
morbidity and mortality in humans. Over the past several years, the molecular and bio‐
chemical pathways that influence the development of colon cancer have been extensively
characterized. Since the development of colon cancer involves multi-step events, the availa‐
ble drug therapies for colorectal cancer are largely ineffective. The radiotherapy, photody‐
namic therapy, and chemotherapy are associated with severe side effects and offer no firm
expectation for a cure. Thus, there is a constant need for the investigation of other potential‐
ly useful options. One of the widely sought approaches is cancer chemoprevention that uses
natural agents to reverse or inhibit the malignant transformation of colon cancer cells and to
prevent invasion and metastasis [33]. Curcumin (diferuloylmethane), a natural plant prod‐
uct, possesses such chemopreventive activity that targets multiple signaling pathways in the
prevention of colon cancer development [34].Colon-targeting delivery of rhubarb extract, as
a purgative, may prevent absorption of free anthraquinones in the upper gastrointestinal
tract, thus improving clinical effects and lowering dosage [35, 36].Chemopreventive effects
of arctiin, a lignin isolated from Arctium lappa (burdock) seeds, on the initiation or post ini‐
tiation period of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) induced mam‐
mary carcinogenesis in female rats and on 2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline
(MeIQx)-associated hepatocarcinogenesis [37].
3. Plant peptides and proteins
Plant peptides and proteins may be considered an overlooked source for new chemical enti‐
ties and novel bioactivities compared to low molecular natural products. The reason for this
seems to be based on tradition and biased by the most commonly used techniques for natu‐
ral products. However, during the last decades, the number of reported plant peptides has
grown substantially, and the field is about to mushroom. In the form of Professor Gunnar
Samuelsson’s’ pioneering studies of mistletoe toxins was reported [38]. In the mid 1990san
attempt to assess plant peptides more broadly, with the design of an isolation protocol di‐
rectly designed for their isolation [39]. One of the results of this effort was the discovery of a
set of macrocyclic peptides in the plant family Violaceae [40]. Strikingly, the peptides we
characterized in Violaceae were found to be nearly identical with one of the most intriguing
examples of pharmacognostic research in general, and plant peptides in particular, namely
the peptide Kalata B1. The discovery of Kalata B1 was based on the ethno-pharmacological
use of the plant Oldenlandia affinis. It was experienced a high frequency of complicated de‐
liveries due to the use of this plant, which was locally known as ‘‘Kalata-Kalata’’ [41]. Na‐
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tive women secretly used a decoction of this plant to facilitate childbirth, which they sipped
as a tea but also applied directly at the birth canal [42]. It induced extremely strong uterine
contractions, which sometimes developed into cervical spasms necessitating acute caesarean
section.
The complete sequence and the cyclic structure was however not determined for more than
20 years later [43].At the time of our report of the first cocktail of ‘‘palate-like’’ peptides in
Violaceae, four similar peptides had been reported in the literature as the serendipitous dis‐
coveries of three independent groups. When including those peptides in a sequence compar‐
ison, i.e. the anti-HIV circulins A and B, the neurotensin binding inhibitor cyclo-psychotride
A and the partially characterized violapeptide I, it was clear that they fell in two subgroups
based on sequencesimilarity. Today, around 150 cyclotides have been reported from species
of three plant families, Violaceae, Rubiaceae and Cucurbitaceae. The family Violaceae seems
to be particularly rich in these proteins [44-47] and a single Violaceae species may contain
more than 60 different cyclotides. It has been suggested that there might be 9,000 cyclotides
in the Violaceae alone[48].
In addition to the amide bond that cyclizes the backbone, cyclotides contain three stabilizing
disulfide bonds in a knotted arrangement, i.e. two disulfides form a ring together with their
connecting protein backbone, which is threaded by the third disulfide [49-51].
CCK motif, and make cyclotides extraordinary stable protein structures [52]. Besides being
uterotonic,anti-HIV, hemolytic and neurotensin binding inhibitory, the list now includes an‐
timicrobial [53], antifouling [54], antihelmintic, molluscicidal, cytotoxic [55, 56]) and insecti‐
cidal activities. The latter effects are some of the most well studied and interesting effects:
the cytotoxic effect together with the haemolytic effect have been the focus for detailed
structure activity studies [57, 58], and the discovery of their insecticidal effect likely revealed
cyclotides’ role in planta. Cyclotides’ mechanism of action is however yet unknown, but evi‐
dence is accumulating showing that membrane interactions followed by membrane pore or
fissure formation are involved [59-61], which could provide an explanation to several of the
reported effects.
Combined with the extraordinary CCK motif—with its conserved scaffold that can be
dressed with variable loop sequences—the demonstrated biological activity of the cyclotides
make them a first class target for protein engineering. To this end, inherent activities of na‐
tive cyclotides can be reinforced or abolished, or new biologically active peptide epitopes
can begrafted into the scaffold. For example, reinforcing the cytotoxic effect could potential‐
ly provide us with leads for anticancer drugs, or to completely remove that effect could pro‐
vide us with an inert scaffold ideal for grafting. The first successful grafting of a
biologicallyactive epitope was reported just recently, showing proof of concept [62].
The success of these strategies relies on the ability of efficient methods for production of cy‐
clotides and cyclotide mutants. Being gene products, cell based production systems seem
promising, but although cyclotide producing plant cell cultures have been established [63],
solid phase peptide synthesis is still the method of choice [64, 65].Our knowledge about
their biosynthesis is yet scarce. We know the structural arrangement of the cyclotide precur‐
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sor from cDNA, and that an asparaginyl endo-peptidase has a likely role for cleaving at the
N terminal side of the mature peptide and that protein disulfide isomerases seem to play a
role for their successful folding. However, the order of the events to produce mature cycloti‐
des is not yet known, i.e. if disulfide bonds are formed before or after excision and ligation,
and nothing is known about how these processes are controlled. In the perspective of ex‐
ploiting the cyclotide scaffold for engineering of bioactive peptides, the possibility of farm‐
ing designed molecules in plantar promises to be the optimal solution; the way there is still
long though.
Matrix metalloproteinase (MMP) are zinc-dependent endopeptidases that mediate numer‐
ous physiologic and pathologic processes, including matrix degradation, tissue remodeling,
inflammation, and tumor metastasis. To develop a vaccine targeting stromal antigens ex‐
pressed by cancer-associated fibroblasts, it was focused on MMP11 (or stromelysin 3).
MMP11 expression correlates with aggressive profile and invasiveness of different types of
carcinoma [66]. Overexpression of IL-12 and IL-23, which share the p40 subunit, has been
implicated in the pathogenesis of Crohn's disease. Targeting these cytokines with monoclo‐
nal antibodies has emerged as a new and effective therapy, but one with adverse reactions
[67]. Intestinal fibrosis and stricture formation are major complications of inflammatory
bowel disease (IBD), for which there are currently few effective treatments. It was investigat‐
ed whether targeting transforming growth factor-beta1 (TGF-beta1), a key profibrotic medi‐
ator, with a peptide-based virus-like particle vaccine would be effective in suppressing
intestinal fibrosis by using a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-in‐
duced chronic colitis [68]. Neutralization of macrophage migration inhibitory factor (MIF)
by anti-MIF antibody reduces intestinal inflammation in mice. Anti-MIF autoantibody in‐
duced by DNA vaccine targeting MIF protects mice against experimental colitis [69].
Overexpression of the proto-oncogene c-Myb occurs in more than 80% of colorectal cancer
(CRC) and is associated with aggressive disease and poor prognosis. To test c-Myb as a ther‐
apeutic target in CRC, which devised a DNA fusion vaccine to generate an anti-CRC im‐
mune response. c-Myb, like many tumor antigens, is weakly immunogenic as it is a "self"
antigen and subject to tolerance [70].Four novel oral DNA vaccines provide protection
against melanoma, colon, breast, and lung carcinoma in mouse models. Vaccines are deliv‐
ered by attenuated Salmonella typhimurium to secondary lymphoid organs and respective‐
ly target vascular endothelial growth factor receptor-2, transcription factor Fos-related
antigen-1, anti-apoptosis protein survivin and Legumain, an asparaginyl endopeptidase
specifically overexpressed on tumor-associated macrophages (TAMs) in the tumor microen‐
vironment (TME). These vaccines are all capable of inducing potent cell-mediated protective
immunity against self-antigens, resulting in marked suppression of tumor growth and dis‐
semination. Key mechanisms induced by these DNA vaccines include efficient suppression
of angiogenesis in the tumor vasculature and marked activation of cytotoxic T cells, natural
killer cells, and antigen-presenting dendritic cells [71]. Shigellosis is a major form of bacil‐
lary dysentery caused by Shigella infection. Shigella ribosome-based vaccines (SRV), consid‐
ered among the potent vaccine candidates, are composed of O-antigen and ribosome
isolated from S. flexneri 2a. The immunogenicity and protective efficacy of SRV was investi‐
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gated and mice were vaccinated with SRV via the intranasal route. Interestingly, robust lev‐
els of Shigella-derived LPS-specific IgG and IgA Abs and antibody-forming cells were
elicited in systemic and mucosal compartments following two intranasal administrations of
SRV. Groups of mice receiving intranasal SRV developed milder pulmonary pneumonia
upon challenge with virulent S. flexneri 2a than did those receiving parenteral SRV [72].
Over the past several years it has become apparent that the tumor stroma represents a sig‐
nificant target for anti-cancer therapies. Therefore we evaluated the strategy of targeting the
tumor stroma with a novel DNA vaccine encoding murine platelet derived growth factor re‐
ceptor-beta (mPDGFRbeta). Immunization with this vaccine induced cytotoxic lysis of
mPDGFRbeta-expressing target cells and protected mice from the growth and dissemination
of murine colon, breast and lung carcinoma. Furthermore, this novel vaccine suppresses an‐
giogenesis in vivo and reduces the numbers of tumor-associated, mPDGFRbeta-expressing
pericytes as suggested by a decrease in intra-tumor expression of mPDGFRbeta and NG2
[73].Viral vectors are under development for anticancer therapy. As they can infect tumors
and activate the immune system, viral vectors may directly destroy cancers (oncolysis), de‐
liver genes with antitumor activity directly to the cancer cells, or act as cancer vaccines. Bet‐
ter insights into the biology of the various vectors in use (e.g., poxvectors, adenovirus,
adeno-associated virus, retrovirus, Newcastle disease virus) are making it possible to engi‐
neer viruses that are more tumor-specific, efficient at tumor infection, and which have en‐
hanced safety due to incorporation of safeguards should dissemination occur [74].
Colorectal carcinoma is a leading cause of cancer-related mortality. Despite the introduc‐
tion of  new cytotoxic drugs,  improved surgical  and radiotherapeutic techniques,  a  large
proportion  of  colorectal  carcinomas  remain  incurable.  New  targeted  therapeutic  strat‐
egies,  including  immunotherapy,  are  being  explored  as  complementary  treatments.  Re‐
cent advances in immunology and molecular biology have opened new avenues for the
clinical testing of rationally designed vaccination strategies against cancer [75].The use of
retrogen plasmid-based vaccine technology to  break tolerance and to  generate  a  robust,
dose-dependent  antibody  response  against  the  self  cancer  antigen,  survivin.  This  phe‐
nomenon  is  due  to  the  incorporation  of  the  survivin  antigen  into  the  retrogen  system
rather than to some peculiarity unique to survivin. In contrast to other genetic immuni‐
zation methods designed to produce antibody responses, the retrogen system results in a
broad range of  antibody isotypes,  indicative of  both a  Th-1 and a Th-2 CD4+ response.
Additional evidence of a Th-1 response is demonstrated by tumor growth inhibition in a
mouse model of colon cancer metastasis [76].
An efficient strategy based on a fully synthetic dendrimeric carbohydrate display (multiple
antigenic glycolpeptide; MAG) to induce anti carbohydrate antibody responses for thera‐
peutic vaccination against cancer was developed. The superior efficacy of the MAG strategy
over the traditional keyhole limpet hemocyanin glycolconjugate to elicit an anticarbohy‐
drate IgG response against the tumor-associated Tn antigen was shown. The influence of the
glycolic carrier elements of such a tumor antigen for their recognition by the immune sys‐
tem was influenced. Finally, we additionally developed the MAG system by introducing
promiscuous HLA-restricted T-helper epitopes and performed its immunological evaluation
Targeting Colon Drug Delivery by Natural Products
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in nonhuman primates. MAG:Tn vaccines induced in all of the animals strong tumor-specif‐
ic anti-Tn antibodies that can mediate antibody-dependent cell cytotoxicity against human
tumor [77].
Overcoming immune tolerance of tumor angiogenesis should be useful for adjuvant therapy
of cancer, which hypothesized that vaccination with autologous endothelium would induce
an autoimmune response targeting tumor angiogenesis.The effect of autologous with a vac‐
cine of glutaraldehyde-fixed murine hepatic sinusoidal endothelial cells (HSEs) was more
pronounced than that of xenogeneic human umbilical vein endothelial cells (HUVECs),
which were tested in the same experimental setting. Its results suggest that vaccination with
autologous endothelium can overcome peripheral tolerance of self-angiogenic antigens and
therefore should be useful for adjuvant immunotherapy of cancer [78].Tumor cells are elu‐
sive targets for immunotherapy due to their heterogeneity and genetic instability. Here, a
novel, oral DNA vaccine that targets stable, proliferating endothelial cells in the tumor vas‐
culature rather than tumor cells was described. Targeting occurs through upregulated vas‐
cular-endothelial growth factor receptor 2 (FLK-1) of proliferating endothelial cells in the
tumor vasculature. This vaccine effectively protected mice from lethal challenges with mela‐
noma, colon carcinoma and lung carcinoma cells and reduced growth of established meta‐
stases in a therapeutic setting. CTL-mediated killing of endothelial cells indicated breaking
of peripheral immune tolerance against this self antigen, resulting in markedly reduced dis‐
semination of spontaneous and experimental pulmonary metastases. Angiogenesis in the tu‐
mor vasculature was suppressed without impairment of fertility, neuromuscular
performance or hematopoiesis, albeit with a slight delay in wound healing [79]. The
HER-2/neu oncogenic protein is a well-defined tumor antigen. HER-2/neu is a shared anti‐
gen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast,
ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-ex‐
istent immune response to HER-2/neu. No matter what the tumor type, endogenous im‐
munity to HER-2/neu detected in cancer patients demonstrates two predominant
characteristics. First, HER-2/neu-specific immune responses are found in only a minority of
patients whose tumors overexpress HER-2/neu. Secondly, immunity, if detectable, is of low
magnitude. These observations have led to the development of vaccine strategies designed
to boost HER-2/neu immunity in a majority of patients. HER-2/neu is a non-mutated self-
protein, therefore vaccines must be developed based on immunologic principles focused on
circumventing tolerance, a primary mechanism of tumor immune escape [80].Listeria mono‐
cytogenes is an intracellular organism that has the unusual ability to live in the cytoplasm of
the cell. It is thus a good vector for targeting protein antigens to the cellular arm of the im‐
mune response. Here, a model system, consisting of colon and renal carcinomas that express
the influenza virus nucleoprotein and a recombinant L. monocytogenes that secrets This an‐
tigen, to test the potential of this organism as a cancer immunotherapeutic agent, which
show that this recombinant organism can not only protect mice against lethal challenge with
tumour cells that express the antigen, but can also cause regression of established macro‐
scopic tumours in an antigen-specific T-cell-dependent manner.
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An efficient strategy for the targeting of anti-tumor effector cells were prepared bispecific
antibody (BsAb) containing anti-CD3 and an anti-c-erbB-2 proto-oncogene product.A troph‐
oblast cell surface antigen has been characterized by a monoclonal antibody (mAb) 5T4,
raised following immunization with solubilized wheat germ agglutinin binding glycopro‐
teins from human syncytiotrophoblast plasma membrane (StMPM) [81].
4. Plant peptides and proteins targets and regulation of this important
pathway
Aberrant activation of the canonical Wnt/beta-catenin pathway occurs in almost all colorec‐
tal cancers and contributes to their growth, invasion and survival. Phospholipase D (PLD)
has been implicated in progression of colorectal carcinoma However, an understanding of
the targets and regulation of this important pathway remains incomplete and besides, rela‐
tionship between Wnt signaling and PLD is not known [82].Fibroblast activation protein is a
product overexpressed by tumor-associated fibroblasts (TAF) and is the predominant com‐
ponent of the stoma in most types of cancer. Tumor-associated fibroblasts differ from nor‐
mal adult tissue fibroblasts, and instead resemble transient fetal and wound healing-
associated fibroblasts. Tumor-associated fibroblasts are critical regulators of tumor genesis,
but differ from tumor cells by being more genetically stable [83]. Capability of human adi‐
pose tissue-derived mesenchyme stem cells (AT-MSC) to serve as cellular vehicles for gene-
directed enzyme prodrug molecular chemotherapy. Yeast fusion cytosine deaminize : uracil
phosphorribosyltransferase expressing AT-MSC (CD y-AT-MSC) combined with systemic 5-
fluorocytosine (5FC) significantly inhibited growth of human colon cancer xenografts [84].
Dendritic cells (DCs), pulsed with the respective endothelium lysates significantly inhibited
the growth of subcutaneous tumors as well as pulmonary metastases in mice, and their anti-
tumor effect was superior to that of unparsed DCs. Immunohistopathological analysis
showed significant decrease in the mean vascular density of tumors, correlating well with
the extent of tumor inhibition. In vitro analysis of splenocytes isolated from immunized
mice revealed an induction of cytotoxic T lymphocytes and activation of natural killer cells,
with a lytic activity against activated endothelium but not tumor cells. In addition, antibod‐
ies reacting with activated endothelium [85]. Crohn's disease (CD) is an inflammatory bowel
disease that is associated with several changes in the immune system, including an in‐
creased number of infiltrating macrophages. These macrophages release a variety of pro-in‐
flammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) which are critically
involved in the onset and the development of CD. The present study was performed to ex‐
plore the initial involvement of macrophages in the development of T-cell-mediated chronic
colitis [86].
Tumor-associated fibroblasts are key regulators of tumor genesis. In contrast to tumor cells,
which are genetically unstable and mutate frequently, the presence of genetically more sta‐
ble fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer
immunotherapy. These cells are also the primary source of collagen type I, which contrib‐
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utes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in
regulating tumor sensitivity to a variety of chemotherapies [87].
Conventional anticancer therapy using cytotoxic drugs lacks selectivity and is prone to tox‐
icity and drug resistance. Anticancer therapies targeting aberrant growth factor receptor sig‐
naling are gaining interest. The erbB receptor family belongs to the type I, the receptor
tyrosine kinases class, and comprises EGFR, HER-2, HER-3, and HER-4. It has been targeted
for solid tumor therapy, including breast, ovarian, colon, head-and-neck, and non-small-cell
lung cancers. Structural aspects of this class of growth factor receptors, their oncogenic ex‐
pression, and various pharmacological interventions including biological products and
small molecules that inhibit these enzymes [88].
Recent reports of tumor regression following delivery of autologous tumor antigen-pulsed
DCs suggest that defective antigen presentation may play a key role in tumor escape. Here,
it is shown in two different murine tumor models, CT26 (colon adenocarcinoma) and B16
(melanoma), that the number and activation state of intratumor DCs are critical factors in
the host response to tumors [89].Epidermal growth factor receptor (EGFR), a member of a
family of membrane receptors with tyrosine kinase activity, is emerging as a target candi‐
date for anti-cancer therapy, due to its overexpression in many carcinomas and its relation‐
ship with several hallmark properties of malignant behavior such as continuous cell
proliferation, escape from apoptosis, cell migration and angiogenesis. Specially appealing is
the overexpression of EGFR in tumors such as lung, colon, kidney and head and neck carci‐
nomas which are mostly resistant to current chemotherapy [90].
It was identified an organic solute transporter (OST) that is generated when two novel gene
products are co-expressed, namely human OSTalpha and OSTbeta or mouse OSTalpha and
OSTbeta. The results also demonstrate that the mammalian proteins are functionally com‐
plemented by evolutionarily divergent OST alpha-OST beta proteins recently identified in
the little skate, Raja erinaceous, even though the latter exhibit only 25-41% predicted amino
acid identity with the mammalian proteins. Human, mouse, and skate OSTalpha proteins
are predicted to contain seven trans membrane helices, whereas the OSTbeta sequences are
predicted to have a single trans membrane helix. co-expression is not required for proper
membrane targeting. Interestingly, OSTalpha and OSTbeta mRNAs were highly expressed
and widely distributed in human tissues, with the highest levels occurring in the testis, co‐
lon, liver, small intestine, kidney, ovary, and adrenal gland [91].Human mucin 1 (MUC1) is
an epithelial mucin glycoprotein that is overexpressed in 90% of all adenocarcinomas in‐
cluding breast, lung, pancreas, prostate, stomach, colon, and ovary. MUC1 is a target for im‐
mune intervention, because, in patients with solid adenocarcinomas, low-level cellular and
humoral immune responses to MUC1 have been observed, which are not sufficiently strong
to eradicate the growing tumor [92]. Efficient T cell priming by GM-CSF and CD40 ligand
double-transduced C26 murine colon carcinoma is not sufficient to cure metastases in a ther‐
apeutic setting [93].
A new therapy against colon cancer was developed and investigated two kinds of strategy
using a cancer-specific approach. First, employed the Cre/loxP regulation system to enhance
the specific expression by carcinoembryonic antigen (CEA) promoter in CEA-producing tu‐
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mor cells, and examined whether sufficient enhancement to transcriptional activity of CEA
promoter, which maintains its specificity in vitro and in vivo, could be obtained. Next, using
dendritic cells pulsed with HLA-A24 epitope peptides of CEA, we performed a Phase I
study of active immunotherapy in patients with advanced colon cancer. These results sug‐
gest that the newly developed therapy for colon cancer is a promising strategy; however,
minor modification may be necessary [94].Serum gastrin is known to be elevated in patients
with liver-metastasizing colon cancer; thus, cholecystokinin (CCK) B/gastrin receptors may
also be up-regulated. A liver-invasive model of colon cancer was established with the hu‐
man colonic cell line C170HM2, which expresses the CCKB/gastrin receptor at both the gene
and protein level. An antiserum has been derived that is directed against the NH2-terminal
17 amino acids of the human CCKB/gastrin receptor coupled to diphtheria toxoid. The pep‐
tide was denoted gastrin receptor protein (GRP) 1[95].2B1 is a bispecific murine monoclonal
antibody (BsMAb) with specificity for the c-erbB-2 and Fc gamma RIII extracellular do‐
mains. This BsMAb promotes the targeted lysis of malignant cells overexpressing the c-
erbB-2 gene product of the HER2/neu proto-oncogene by human natural killer cells and
mononuclear phagocytes expressing the Fc gamma RIII A isoform [96-98].
5. Methods of targeting colon drug delivery by natural products
The various targeting methods to the colon include coating with pH dependent polymers,
degradation by bacteria, specially azo-cross linked polymers and certain polysaccharides
such as pectin and guar gum are good carriers for formulation, which are presented in Table
1.To achieve successful colonic delivery, a drug needs to be protected from absorption and
the environment of the upper gastrointestinal tract and then be released into the proximal
colon, which is considered the optimum site for colon targeted delivery of natural com‐
pounds. Colon targeting is naturally of value for the treatment of diseases of colon such as
Chron’s disease, ulcerative colitis, and colorectal cancer.
6. Classification of targeting colon drug delivery system
Colon targeting drug delivery system is classified into three categories greatly and the rele‐
vant developed systems are published in many reports.
Firstly, Local Therapy - Higher local drug level can be achieved while minimizing side ef‐
fects that occur due to the release in the upper GIT.The system can treat local disease effec‐
tively such as constipation, irritable bowel disease and colon cancer.
Secondly,DelayedOnset - Maximal plasmalevel can be achieved in the morning hours after
bedtime administration by delayed onset of the system to adjust the circadian variations in
the signs and symptoms of disease such asrheumatoid arthritis, hypertension and etc.
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Thirdly,Protein and Peptide Delivery - The colon is a "friendlier" environment for proteins,
peptides and vaccines compare to the upper GIT. Clinically relevant bioavailability may be
achieved if the drugs can be protected from the upper GIT.
7. Local targeting colon drug delivery
It was evaluated that colon targeting characteristic of Kuikang colon targeted pellets (KCP)
with determination of residual baicalin and baicalein concentration in gastrointestinal tract
(GIT).The major challenges in targeting drug to various parts of the gastrointestinal tract in‐
clude control of drug release with respect to its environment and transit time. These two
variables should be taken into consideration in designing a rational colonic drug delivery
system. To this end, a swelling matrix core containing pectin, hydroxylpropyl methylcellu‐
lose (HPMC), microcrystalline cellulose and 5-aminosalicylic acid was developed. This was
subjected to a dual coating operation: an inner pH-sensitive enteric and an outer semi-per‐
meable membrane coat with a pore former [99-101].
A pectin-hydroxylpropyl methylcellulose coating was compressed onto core tablets labeled
with 4MBq (99m)Tc-DTPA. Prolonged residence at the ICJ is assumed to have increased hy‐
dration of the hydrogel layer surrounding the core tablet. Forces applied as the tablets pro‐
gressed through the ICJ may have disrupted the hydrogel layer sufficiently to initiate
radiolabel release. Inadequate prior hydration of the hydrogel layer preventing access of
pectinolytic enzymes and reduced fluid availability in the TC may have retarded tablet dis‐
integration and radiolabel diffusion.
8. Delayed onset for targeting colon drug delivery
A multiparticulate system having pH-sensitive property and specific enzyme biodegradabil‐
ity for colon-targeted delivery of metronidazole was developed [102]. Pectin microspheres
were prepared using emulsion-dehydration technique. These microspheres were coated
with Eudragit(R) S-100 using oil-in-oil solvent evaporation method. The in vivo studies were
also performed by assessing the drug concentration in various parts of the GIT at different
time intervals which exhibited the potentiality of formulation for colon targeting. Hence, it
can be concluded that Eudragit coated pectin microspheres can be used for the colon specific
delivery of drug.
Designing pH-sensitive, polymeric nanoparticles of curcumin, a natural anti-cancer agent,
for the treatment of colon cancer, which enhance the bioavailability of curcumin, simultane‐
ously reducing the required dose through selective targeting to colon [103]. Eudragit S100
was chosen to aid targeting since the polymer dissolves at colonic pH to result in selective
colonic release of the entrapped drug. Solvent emulsion-evaporation technique was em‐
ployed to formulate the nanoparticles. The combined influence of 3 independent variables in
the compression coated tablet of mesalamine [104] for ulcerative colitis. A 3-factor, 3-level
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Box-Behnken design was used to derive a second order polynomial equation and construct
contour plots to predict responses. The independent variables selected were: percentage of
polymers (pectin and compritol ATO 888) in compression coating (X(1)), coating mass (X(2))
and coating force (X(3)). Fifteen batches were prepared and evaluated for percent of drug
released in 5 h (Y(5)), time required for 50 % mesalamine to dissolve (t(50)) with rat cecal
(RC) content and without rat cecal content (t(50)), percent of drug released in 24 h in the
presence of rat cecal content (Y(24) with RC) [105].
The colon specificity of novel natural polymer kaya gum and compare with guar gum. Re‐
lease profile of tablets was carried out in presence and absence of rat cecal contents. The fast
disintegrating core tablets of budesonide, were initially prepared by direct compression
technique. Later, these tablets were coated with kaya gum or guar gum. After suitable pre
compression and post compression evaluation, these tablets were further coated using Eu‐
dragit L-100 by dip coating technique [106].Enteric-coated calcium pectinase microspheres
(MS) aimed for colon drug delivery have been developed, by using theophylline as a model
drug. The influence of pectin type (animated or non-animated) and MS preparation condi‐
tions (CaCl2) concentration and cross-linking time) was investigated upon the drug entrap‐
ment efficiency and its release behavior. Pectin/ethyl cellulose-film-coated pellets of 5-
fluorouracil (5-FU) [107] for colonic targeting were characterized. The pellet cores were
coated to different film thicknesses with three different pectinethyl cellulose formulations
using a fluidized bed coater [108]. The gastrointestinal (GI) transit of coated pellets was de‐
termined by counting the percentage of coated pellets in the GI lumen by celiotomy at cer‐
tain times after oral administration. 5FU was administered to rats at a dose of 15 mg kg(-1).
The toxicity of 5-FU in the GI tract was evaluated using histological examination. The 1:2 ra‐
tio pectin:ethyl cellulose-coated pelletswith 30% total weight gain (TWG-30%) produced
more satisfactory drug-release profiles in the simulated gastric, intestinal and colonic fluids
[109]. Most of the coated pellets were eliminated from the stomach in 2 h, moved into the
small intestine after 2-4 h, and reached the large intestine after 4 h.A novel colon targeted
tablet formulation was developed using natural polysaccharides such as chitosan and guar
gum as carriers and diltiazem hydrochloride as model drug [110]. The prepared blend of
polymer-drug tablets were coated with two layers, inulin as an inner coat followed by shel‐
lac as outer coat and was evaluated for properties such as average weight, hardness and
coat thickness. In vitro release studies of prepared tablets were carried out for 2 h in pH 1.2
HCl buffers, 3 h in pH 7.4 phosphate buffer and 6 h in simulated colonic fluid (SCF) in order
to mimic the conditions from mouth to colon. Coated micro-pellets of pH-dependent and
enzyme-dependent kangfuxin colon targeting delivery system were prepared; to make them
go to colon, then release, educe partial effect [111].
The ingredients for preparing the micro-pellets are 125% starch +2% CMC-Na, and add 30%
ethanol to be binder, pellets were coated with Eudragit S100 to prepare pH-dependent and
pectin-HPMC to prepare enzyme-dependent colon targeting micro-pellets.
Guar gum/ethyl cellulose mix coated pellets for potential colon-specific drug delivery were
designed [112, 113]. The coated pellets, containing 5-fluorouracil as a model drug, were pre‐
pared in a fluidized bed coater by spraying the aqueous/ethanol dispersion mixture of guar
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gum and ethyl cellulose. The lag time of drug release and release rate were adjustable by
changing the ratio of guar gum to ethyl cellulose and coat weight gain. In order to find the
optimal coating formulation that was able to achieve drug targeting to the colon and con‐
cluded that mixed coating of guar gum and ethyl cellulose is able to provide protection of
the drug load in the upper gastrointestinal tract, while allowing enzymatic breakdown of
the hybrid coat to release the drug load in the colon.A pectin-based colon specific delivery
system bearing 5-fluorouracil (5-FU) was developed for effective delivery of drug to the co‐
lon. Calcium pectinate gel (CPG) beads were prepared by ion tropic gelation method fol‐
lowed by enteric coating with Eudragit S-100 [114, 115]. The CPG beads formed were
spherical with smooth surfaces.Eudragit S-100 coated calcium pectinate beads delivered
most of its drug load (93.2+/-3.67%) to the colon after 9 h, which reflects its targeting poten‐
tial to the colon. It is concluded that orally-administered 5-FU loaded Eudragit S-100 coated
calcium pectinate beads can be used effectively for the specific delivery of drug to the co‐
lon.Colon-targeted drug delivery systems for 5-fluorouracil using pectin combined with eth‐
yl cellulose as a film coat with fluidized bed coater were de4veloped. Pellets (0.8-1.0 mm in
diameter) containing 40% 5-fluorouracil and 60% microcrystalline cellulose were prepared
by extrusion and spheronization.Eudragit-coating of pectin microspheres was performed by
oil-in-oil solvent evaporation method using coat: core ratio (5:1). The release profile of FU
from Eudragitcoated pectin microspheres was pH dependent. In acidic medium, the release
rate was much slower; however, the drug was released quickly at pH 7.4. It is concluded
from the present investigation that Eudragitcoated pectin microspheres are promising con‐
trolled release carriers for colon-targeted delivery of FU.
Guar gum-based matrix  tablets  of  rofecoxib for  their  intended use in the chemopreven‐
tion  of  colorectal  cancer  were  developed and evaluated  [116].  Matrix  tablets  containing
40% (RXL-40), 50% (RXL-50), 60% (RXL-60) or 70% (RXL-70) of guar gum were prepared
by wet granulation technique. Colon delivery of beta-lactamases by pectin beads aiming
to degrade residual beta-lactam antibiotics, in order to prevent the emergence of resistant
bacterial strains[115]. Pectin beads were prepared according to inotropic gelation method
using CaCl2  as a gelling agent[117]. Particles were then washed and soaked in polyethy‐
leneimine (PEI). Coating beads with PEI considerably improved their stability in simulat‐
ed intestinal medium.
9. Polysaccharides as a strategy for targeting colon drug delivery
A variety of delivery strategies and systems have been proposed for colonic targeting. These
generally rely on the exploitation of one or more of the following gastrointestinal features
for their functionality: pH, transit time, pressure or micro flora. Coated systems that utilise
the pH differential in the gastrointestinal tract and prodrugs that rely on colonic bacteria for
release have been commercialized. Both approaches have their own inherent limitations.
Many systems in development have progressed no further than the bench, while others are
expensive or complex to manufacture, or lack the desired site-specificity. The universal pol‐
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ysaccharide systems appear to be the most promising because of their practicality and ex‐
ploitation of the most distinctive property of the colon, abundant micro flora.
Recent research into the utilization of the metabolic activity and the colonic microenviron‐
ment in the lower gastrointestinal tract has attained great value in the design of novel colon-
targeted delivery systems based on natural biodegradable polymers. In the current articles,
special emphasis has been placed on polysaccharide systems, with minimal chemical modi‐
fication, that have been exploitedfor colon targeting. These polysaccharide based encapsula‐
tion and targeted delivery systems are envisaged to have an immense potential for the
development of food/nutraceutical formulations for colon-based diseases, including colorec‐
tal cancer [118].Pectin-ketoprofen (PT-KP) prodrug with the potential for colon targeted de‐
livery has been evaluated and showed KP distributes mainly in stomach, proximal small
intestine and distal small intestine. However, KP released from PT-KP mainly distributes in
cecum and colon. Therefore, this approach suggests that PT-KP prodrug has a good colon
targeting property [119].
Compression coatings for target drug delivery to the colon using indometacin (a water in‐
soluble drug) and paracetamol (a water soluble drug) as model drugs were evaluated. The
core tablets were compression-coated with 300 and 400 mg of 100% kayas gum, 100% albizia
gum and a mixture of kaya and albizia gum (1:1). Colon targeted drug delivery systems
were developed for tinidazole using guar gum as a carrier in the treatment of amoebiasis.
Fast-disintegrating tinidazole core tablets were compression-coated with 55, 65 and 75% of
guar gum [120]. Colon-targeted drug delivery systems for ornidazole [121]using guar gum
as a carrier are developed.The core formulation containing ornidazole was directly com‐
pressed. Compression-coated tablets of ornidazole containing various proportions of guar
gum in the coat were prepared. Compression-coated ornidazole tablets with either 65%
(OLV-65) or 75% (OLV-75) of guar gum coat are most likely to provide targeting of ornida‐
zole for local action in the colon owing to its minimal release of the drug in the first 5 hr. The
ornidazole compression-coated tablets showed no change in physical appearance, drug con‐
tent, or in dissolution pattern after storage at 40 degrees C/75% relative humidity for 6
months [122-125].
Novel tablet formulations for site-specific delivery of 5-fluorouracil to the colon without the
drug being released in the stomach or small intestine using guar gum as a carrier were de‐
veloped. Fast-disintegrating 5-fluorouracil core tablets were compression coated with 60%
(FHV-60), 70% (FHV-70) and 80% (FHV-80) of guar gum [126]. Oral colon-targeting drug de‐
livery systems for celecoxib using guar gum as a carrier were developed. Matrix tablets con‐
taining various proportions of guar gum were prepared by wet granulation technique using
starch paste as a binder.Colon targeted drug delivery systems for metronidazole using guar
gum as a carrier were developed. Matrix, multilayer and compression coated tablets of met‐
ronidazole containing various proportions of guar gum were prepared [127].The influence
of metronidazole and tinidazole on the usefulness of guar gum, a colon-specific drug carrier
based on the metabolic activity of colonic bacteria, using matrix tablets of albendazole (con‐
taining 20% of guar gum) as a model formulation is reported.Colon targeted drug delivery
systems for mebendazole using guar gum as a carrier were developed. Matrix tablets con‐
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taining various proportions of guar gum were prepared by wet granulation technique using
starch paste as a binder [128, 129].
Controlling the delivery of drugs to different regions of the colon remains an elusive goal‐
was to define the diurnal variation in colonic transit and show how this influences the co‐
lonic distribution and residence time of different formulations given either in the morning
or evening. Colonic transit of small particulates and a large capsule was measured during
nocturnal sleep and daytime wakefulness. Sleep delays colonic transit and large capsules
travel faster than dispersed small particles. However, substantial inter-individual variability
in transit makes targeting specific regions of the human colon unreliable with either dis‐
persed or single unit formulations [130].
Targeting of drugs to the colon, following oral administration, can be accomplished by the
use of modified, biodegradable polysaccharides as vehicles. In a previous study, a cross‐
linked low swelling guar gum (GG) hydrogel was synthesized by reacting it with trisodium
trimetaphosphate (STMP). In the present study the functioning of GG crosslinked products
(GGP) as possible colon-specific drug carriers was analyzed by studying (a) the release ki‐
netics of pre-loaded hydrocortisone from GGP hydrogels into buffer solutions with, or with‐
out GG degrading enzymes (alpha-galactosidase and beta-mannanase) and (b) direct
measurements of the polymers' degradation [131]. Calcium pectinate preparations for drug
delivery to the colon were investigated and highlight the value of scintigraphy in focusing
the development strategy for colonic targeting preparations.
One of the review articles concluded that polysaccharide-based colon-targeted drug deliv‐
ery systems are effective when they are precisely activated by the physiological conditions
of the colon. Absence of enzymes during colonic disorders might hinder the activation of the
delivery system. To guarantee delivery of the drug to the colon, it is preferable to combine
polysaccharides with enteric or cellulose polymers [132]. The approach that is based on the
formulation of natural polysaccharides has been used as tools to deliver the drugs specially
to the colon as described in Table 1 and Table 2.
These polysaccharides remain intact in the physiological environment of stomach and small
intestine but once the dosage form enters into colon, it is acted upon by polysaccharides,
which degrades the polysaccharide and release the drug into the vicinity of bio-environment
of colon (Table 3).As shown in Figure 1 the designed drug delivery systems have been de‐
veloped that are based on the principle to prevent release of drug until 3-4 h after leaving
the stomach, which are correspond to blood concentration profile as illustrated in Figure 2.
With the respect to natural products improved drug delivery systems are required for drugs
currently in use to treat localized disease of the colon. The advantages of targeting drugs
specially to the diseased colon are reduced incidence of systemic side effects, lower dose of
drug, supply of the drug to the bio phase only when it is required and maintenance of the
drug its intact form as close as possible to target site. Thus, the natural and modified proper‐
ties of polysaccharides that are responsible for their colon targeting abilities. Among the dif‐
ferent approaches used, polysaccharides that are precisely activated by the physiological
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conditions of the colon hold great promise, as they provide improved site specificity and
meet the desired therapeutic needs.
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Polysaccharides Main Chains Side Chains Bacterial Species
Pectin 1) α-1,4 D-garactouronicacid
2) 1,2 –L-rhamnose
D-galactose
L-arabinose
Bacteroides ,
Bifidobacteria,
Eubacteria
Guar Gum 1) α-1,4 D-mannose
2) α-1,3 or α-1,4 D-galactose
α-1,6 D-galactose Bacteroides ,
Ruminococci
Amylose α-1,4 D-glucose -  
Chitosan Deacetylated β-1,4 N-acetyl-D-
glucosamine
-  
Chondroitin
Sulfate
1) β-1,3 D-glucuronicacid
2) N-acetyl-D-glucosamine
- Bacteroides
Cyclodextrine α-1,4 D-glucose - Bacteroides
Dextran α-1,6 D-glucose α-1,3 D-glucose Bacteroides
Xylan β-1,4 D-xylose β-1,3 L-arabinose Bacteroides ,
Bifidobacteria
Table 1. Main Structural Features of Polysaccharides
System CoLar ® CSDS Colon Delivery System
Developer Allyzyme (U.K ) Samyang Co., ( Korea ) Perio ( Israel )
Composition Amylose+Ethylcellulose Coating Tablet or Soft capsule coated
with Polysaccharide
1) Fast release: Ca.P + P
2) Slow release:Ca.P + GG
Dosage form Coated Tablet Coated Tablet
Coated Soft Capsule
Matrix Tablet
Drug Rensapride Budesonide,
Mesalazine
Diclofenac
Prednisolone
Theophylline
Diclofenac
Insulin
Indication Constipation
Predominant
I.B.S.
I.B.D.
Rheumatoid
Arthritis
Rheumatoid Arthritis
Diabetes
Stage PhaseI(Japan)
PhaseII (U.K)
System
Development
System Development System Development
Licensee S.K.B
Now discontinuedfor internal
reason
Alpharma Co.,
Table 2. Microbial Degradable Colon Delivery System.
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System Targit ® Chronotopic ® CTDC ® Colon Delivery
System
Developer DanBio System ( U.K ) Poli Chemical Industry
(Italy)
Tanabe Seiyaku
(Japan)
Chiesi (Italy )
Composition Starch Capsule +
Enteric Coating
1) 1st : Core Tablet
2)2nd:Low-Viscosity
HPMC
3) 3rd : Eudragit
1) 1st layer: Eudragit L
2) 2nd layer: HPMC
3) 3rd layer: Eudragit E
Enteric(Eudragit–S)
Coating
Dosage
form
Coated Capsule Coated tablet Coated Capsule Coated Tablet
Drug Mesalazine Mesalazine Prednisolone
Theophylline
Beclomethasone
Dipropionate
Indication I.B.D. I.B.D. - I.B.D.
Stage System Development Phase II ( Italy ) System Development Phase III ( Italy )
Licensee Western Pharma. - - -
Table 3. Time-Controlled &pH-Controlled Colon Delivery System
10. Protein and peptide drug targeting colon delivery
Targeted delivery to the gastrointestinal tract requires a multi-disciplinary approach to re‐
search involving contributions from polymer and material scientists, gastroenterologists,
pharmaceutical scientists and technologists. Intestinal delivery is important not only for
drugs that act locally, but also for those with systemic activity [133, 134]. In particular, there
is considerable interest in the oral delivery of peptides and it is felt that the colon may pro‐
vide an advantageous absorption site for such molecules. The different targeting mecha‐
nisms available to the pharmaceutical scientist to provide site-specific delivery in the
gastrointestinal tract will be critically assessed. Delivery systems and targeting agents,
which are being developed for the delivery of drugs, may also be exploited for the delivery
of vaccines, since many of the delivery problems are common to both areas. Recent develop‐
ments in the design of oral antigen formulations was discussed in this review [135-137].
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